Ann: Europe Patent to be Granted for PD1-Vaxx Cancer Vaccine, page-64

In October 2023 Keytruda brought in more than $6.3 billion USD inthird-quarter sales, a 17% increase from the same period last year, placing annual forecast sales at close to $25 Billion USD.
Opdivo needed $9.3 Billion USD last year.
Tercentriq, the drug currently in combination with PD1 Vaxx to treat cancer patients, is forecast to earn close to $5 billion USD this year.

PD1 Vaxx didn't earn anything. But only as it has not fully evolved yet. Preliminary PD1 Vaxx results were outstanding, with complete and partial responses evident in seriously ill lung cancer patients. No significant side effects were evident, as are so often associated with the above mentioned products. Hey one patient with late stage lung cancer is still walking around having been treated in the Phase 1 PD1 Vaxx trial. How good is that!

Lung cancer, colon cancer, colorectal and other prospective cancer indications have diagnosis' in the collective millions on a per annum basis. PD1 Vaxx has a burgeoning market, given the rise of the middle class worldwide. Adding to its value proposition is the fact regulators are chasing safer more cost effective drugs. It is therefore worth noting PD1 Vaxx can be manufactured at a fraction of the cost of the aforementioned competitors, promising Big Pharma margins even greater than in todays drugs. Whilst it goes without saying, today PD1 Vaxx has extended patent life globally, as opposed to the aforementioned drugs, who in many instances are facing the tumultuous patent cliff.

At higher dose rates than the initial PD1 Vaxx Trial, efficacy should prove even better this time around, as patient immune systems are stimulated through the administration of increased levels of the B Cell drug. I believe PD1 Vaxx's inventor Professor Kaumaya has stated the potential of PD1 Vaxx when combined with other immunotherapies is enormous. I would take him at his word, given he has been recognised as an innovator of the year within the oncology market segment.

Don't throw the baby out with the bath water due to the lack of SP action on any given day. PD1 Vaxx promises to be a serious contender to all the aforementioned blockbusters, worth a truck load more than the overall IMU market cap put together, if these competitor sales are anything to go by. Today is another step forward, for the more cancer indications PD1 Vaxx is endorsed in, the closer this remarkable drug comes to assuming the mantle of an industry leader, alongside its lucrative competitors. Clinical trials take time. Rome wasn't built in a day, but when it was it was pretty huge.

DYOR Seek investment advice as and when required Opinions only